Thera4Care will establish a European Union (EU) network of radiotheranostics centres able to rapidly develop and implement radiotheranostics tools and solutions to drive precision health. The overarching vision of Thera4Care is to revolutionise radiotheranostics procedures by establishing, implementing, and disseminating standardised scalable methods to produce and efficiently administer key radiotheranostics solutions. Thera4Care focuses on developing diagnostic and therapeutic ligands tailored to key disease areas (such as solid tumours), aligning with the growing significance of multi-modal radiotheranostics solutions dominated by radionuclide-based therapy and companion diagnostics. These solutions are emerging as safe, personalised, and effective approaches for treating various diseases. However, the current utilisation of such therapies is limited to a few specialised centres, necessitating an increase in clinical treatment capacities. Additionally, there is a need to broaden the arsenal of radiotheranostics, potentially incorporating novel non-nuclear approaches. In the context of this broader vision, Thera4Care aims to leverage or create standardised and scalable radiochemical methods for labelling, developing, and producing diagnostic and therapeutic ligands. This includes the exploration of new, and innovative combinations of existing multi-modal radiotheranostics, encompassing both radiopharmaceuticals and non-radioactive solutions. The main aim is to address the challenge of limited accessibility to these advanced therapies, especially in the context of diseases with unmet public health needs, such as oncology, neurology, and advanced multi-disease conditions.
To further support Thera4Care’s vision, the consortium intends to establish precise positron emission tomography (PET) and Single-photon emission computed tomography (SPECT) imaging-based diagnostic and therapy monitoring protocols for the identified radiotheranostics ligands. Simultaneously, Thera4Care is committed to developing standardised and scalable dosimetry, quantitation, therapy-selection, and timely supply methodologies to ensure precise treatment and optimise patient outcomes. Furthermore, we envision the creation of an approved clinical trial master protocol designed for evaluating radiotheranostics procedures in hospitalised patients during phase I/IIa trials. This master protocol, developed through a collaborative European effort, will accelerate the time to treat patients with promising radiotheranostics procedures.
In this pursuit of innovation, Thera4Care is dedicated to preclinically exploring various compound/radionuclide combinations in cancer indications with unmet medical needs, such as solid tumours. Subsequently, clinical proof-of-concept evaluations will be performed for the most promising radiotheranostics solutions identified through the master protocol's development. The comprehensive approach of the project aims to propel the field of radiotheranostics, addressing critical medical challenges and improving patient care.
